Skip to main content
Search
News, Views, and Advocacy From the Oncology Nursing Society
ONS Voice Home
  • News & Views
  • Advocacy
  • Stories
  • Instagram
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • RSS
  • News & Views
    • Latest Articles
    • Clinical Practice
    • ONS News
    • ONS Leadership
    Trending Topics
    • Treatments
    • Research
    • Safety
    • COVID-19
    • ONS Congress
    • Clinical practice
    View All Topics
    Advocacy
    • Latest Articles
    • Updates
    • Get Involved
    Stories View All
    View All
    Zoom Through Video Job Interviews With These Tips for Applicants and Hiring Managers
    nursing professional development
    Zoom Through Video Job Interviews With These Tips for Applicants and Hiring Managers
    January 22, 2021
    The Case of Concurrent Therapy Concerns
    Treatment side effects
    The Case of Concurrent Therapy Concerns
    December 18, 2020
    In a World Where You Can Be Anything, Be Kind
    Nurse staffing
    In a World Where You Can Be Anything, Be Kind
    December 11, 2020
    Nursing Innovation Links Rural Facilities to Resources and Experts to Provide High-Quality Care Across the Country
    Access to cancer care
    Nursing Innovation Links Rural Facilities to Resources and Experts to Provide High-Quality Care Across the Country
    December 04, 2020
    Why All Oncology Nurses Should Be Environmentalists
    Oncology nurse influence
    Why All Oncology Nurses Should Be Environmentalists
    November 27, 2020
    previous slide
    next slide
    Search
  • News & Views
  • Advocacy
  • Stories
  • Topic

    Treatments

    COVID-19 Reference Sheet: Vaccines
    COVID-19

    COVID-19 Reference Sheet: Vaccines

    To control the COVID-19 coronavirus pandemic, we need public health measures (e.g., masks, physical distancing, hand washing), treatments for infection, and vaccines to prevent infection or serious disease. In 2020, several manufacturers developed COVID-19 vaccines in less than a year. Before that, the fastest a vaccine had been developed was in four years.  

    December 14, 2020
    COVID-19 Drug Reference Sheet: Bamlanivimab
    COVID-19

    COVID-19 Drug Reference Sheet: Bamlanivimab

    On November 9, 2020, the U.S. Food and Drug Administration (FDA) issued an emergency use authorization for bamlanivimab, an unapproved agent, to treat mild to moderate cases of the COVID-19 coronavirus. EUAs are not FDA approvals; rather, they authorize use of an unapproved medication in an emergency setting. Bamlanivimab’s initial supply is limited, but the manufacturer announced increased production and distribution in early 2021.

    November 20, 2020
    Educational Framework Offers Guidance for Oral Chemo Safety at Home
    Safety

    Educational Framework Offers Guidance for Oral Chemo Safety at Home

    One aspect that ambulatory oncology nurses must consider in the greater staffing conversation is the time spent on educating patients and caregivers about oral chemotherapy safety in the home setting. Developing an educational framework to guide those conversations not only ensures that all critical information is covered but also that it’s delivered in a standard and efficient process. 

    March 10, 2020
    FDA Approves Isatuximab-irfc for Multiple Myeloma
    U.S. Food and Drug Administration (FDA)

    FDA Approves Isatuximab-irfc for Multiple Myeloma

    On March 2, 2020, the U.S. Food and Drug Administration (FDA) approved isatuximab-irfc (Sarclisa®) in combination with pomalidomide and dexamethasone for adult patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor.

    March 02, 2020
    FDA Approves Neratinib for Metastatic HER2-Positive Breast Cancer
    U.S. Food and Drug Administration (FDA)

    FDA Approves Neratinib for Metastatic HER2-Positive Breast Cancer

    On February 25, 2020, the U.S. Food and Drug Administration (FDA) approved neratinib (Nerlyn®) in combination with capecitabine for adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 based regimens in the metastatic setting.

    February 26, 2020
    Oncology Drug Reference Sheet: Niraparib
    Treatments

    Oncology Drug Reference Sheet: Niraparib

    Niraparib was approved in October 2019 for patients with homologous recombination deficiency (HRD)-positive advanced ovarian, fallopian tube, or primary peritoneal cancer. 

    February 25, 2020
    The Case of the CDK4/6 Inhibitors Checklist
    Immunotherapy

    The Case of the CDK4/6 Inhibitors Checklist

    Three years ago, Sarah, age 54, completed standard chemotherapy and radiation treatment for stage II, ER- and PR-positive, HER2-negative invasive breast cancer. A recent computed tomography scan, ordered to evaluate persistent hip pain, revealed bone lesions, and a biopsy and positron-emission tomography scan confirmed bone-only metastatic breast cancer. A CDK4/6 inhibitor, ribociclib, was added to the letrozole she was already taking.

    February 18, 2020
    Nurses Will Forge New Territory With Biosimilars in Cancer Care
    Treatments

    Nurses Will Forge New Territory With Biosimilars in Cancer Care

    Although cancer biosimilars have been used in European countries and in U.S. supportive care for some time, biologic medications are still new to cancer treatment in the United States. With greater support coming in at the federal level and from agencies like the U.S. Food and Drug Administration (FDA) and Federal Trade Commission, the rising biosimilar tide could soon reach a new highwater mark for healthcare professionals—and nurses specifically.

    February 13, 2020
    Immune-Related Adverse Events With PD-1 Inhibitors in Head and Neck Cancer
    Clinical practice

    Immune-Related Adverse Events With PD-1 Inhibitors in Head and Neck Cancer

    Clinical trial results show that PD-1 inhibitors offer improved survival and a better safety profile compared to standard, single-agent chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck. However, because of their mechanism of action as immunotherapy, patients receiving the agents may experience immune-related adverse events (irAEs).

    February 11, 2020
    Study Drug Plus Immunotherapy May Offer New Treatment Option for Lung and Kidney Cancer
    Treatments

    Study Drug Plus Immunotherapy May Offer New Treatment Option for Lung and Kidney Cancer

    Pegilodecakin, an investigational, first-in-class drug currently in clinical trials, is demonstrating positive safety results and measurable responses when used in combination with pembrolizumab or nivolumab in patients with non-small cell lung cancer (NSCLC) or kidney cancer. The findings from the multicenter, phase IB study were published in Lancet Oncology.

    January 28, 2020
    Prostate Cancer Prevention, Screening, Treatment, and Survivorship Recommendations
    Prostate cancer

    Prostate Cancer Prevention, Screening, Treatment, and Survivorship Recommendations

    One in nine men will be diagnosed with prostate cancer, the second leading cause of death in men in the United States. Survival varies greatly depending on the disease’s severity and extent at diagnosis: five-year survival rates are near 100% for local or regional disease, but they drop to 30% for metastatic prostate cancer.

    January 27, 2020
    FDA Approves Tazemetostat for Advanced Epithelioid Sarcoma
    U.S. Food and Drug Administration (FDA)

    FDA Approves Tazemetostat for Advanced Epithelioid Sarcoma

    On January 23, 2020, the U.S. Food and Drug Administration (FDA) granted accelerated approval to tazemetostat for adults and pediatric patients aged 16 years and older with metastatic or locally advanced epithelioid sarcoma not eligible for complete resection.

    January 24, 2020
    Trastuzumab Biosimilar Has Comparative Safety and Efficacy After Long-Term Follow-Up
    Treatments

    Trastuzumab Biosimilar Has Comparative Safety and Efficacy After Long-Term Follow-Up

    January 22, 2020
    Oncology Drug Reference Sheet: Entrectinib
    Treatments

    Oncology Drug Reference Sheet: Entrectinib

    Entrectinib was approved by the U.S. Food and Drug Administration in August 2019 as the third tumor-agnostic cancer drug, meaning it targets a specific mutation of the cancer, not the organ of origin. The other two currently approved tumor-agnostic drugs are larotrectinib and pembrolizumab.

    January 21, 2020
    FDA Approves Avapritinib for Gastrointestinal Stromal Tumor With a Rare Mutation
    U.S. Food and Drug Administration (FDA)

    FDA Approves Avapritinib for Gastrointestinal Stromal Tumors With a Rare Mutation

    On January 9, 2020, the U.S. Food and Drug Administration (FDA) approved avapritinib (AyvakitTM) for adults with unresectable or metastatic gastrointestinal stromal tumor harboring a platelet-derived growth factor receptor alpha exon 18 mutation, including D842V mutations.

    January 10, 2020
    FDA Approves Pembrolizumab for BCG-Unresponsive, High-Risk Non-Muscle Invasive Bladder Cancer
    U.S. Food and Drug Administration (FDA)

    FDA Approves Pembrolizumab for BCG-Unresponsive, High-Risk Non-Muscle Invasive Bladder Cancer

    On January 8, 2020, the U.S. Food and Drug Administration (FDA) approved pembrolizumab for the treatment of patients with Bacillus Calmette-Guerin unresponsive, high-risk, non-muscle invasive bladder cancer with carcinoma in situ with or without papillary tumors who are ineligible for or have elected not to undergo cystectomy.  

    January 08, 2020
    Oral Chemo Education Sheets Provide Key Education to Patients
    Patient Education

    Oral Chemo Education Sheets Provide Key Information to Patients

    Oral oncolytics have introduced a different level of complexity to care. Many patients won’t ever receive their treatments in the infusion room, which is where nurses have traditionally offered in-depth patient education. Instead, nurses are using new tools—like the Oral Chemo Education Sheets—to ensure patients have the information they need to understand their treatment and its side effects.

    January 01, 2020
    Oncology Drug Reference Sheet: Radium 223 Dichloride
    Treatments

    Oncology Drug Reference Sheet: Radium 223 Dichloride

    Radium 223 dichloride (Xofigo®) is an alpha particle-emitting radioactive therapeutic agent approved by the U.S. Food and Drug Administration in 2013 for castrate-resistant prostate cancer.

    December 24, 2019
    FDA approves fam-trastuzumab deruxtecan-nxki for unresectable or metastatic HER2-positive breast cancer
    U.S. Food and Drug Administration (FDA)

    FDA Approves Fam-Trastuzumab Deruxtecan-Nxki for Unresectable or Metastatic HER2-Positive Breast Cancer

    On December 20, 2019, the Food and Drug Administration granted accelerated approval to fam-trastuzumab deruxtecan-nxki (Enhertu®) for patients with unresectable or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting.

    December 20, 2019
    FDA Grants Accelerated Approval to Enfortumab Vedotin-ejfv for Metastatic Urothelial Cancer
    U.S. Food and Drug Administration (FDA)

    FDA Grants Accelerated Approval to Enfortumab Vedotin-ejfv for Metastatic Urothelial Cancer

    On December 18, 2019, the U.S. Food and Drug Administration granted accelerated approval to enfortumab vedotin-ejfv (PadcevTM) for adult patients with locally advanced or metastatic urothelial cancer who have previously received a programmed death receptor-1 (PD-1) or programmed death-ligand 1 inhibitor, and a platinum-containing chemotherapy in the neoadjuvant/adjuvant, locally advanced or metastatic setting.

    December 19, 2019
    Combining Tamoxifen and Blue Light Can Better Target CAR T Cells
    Research

    Combining Tamoxifen and Blue Light Can Better Target CAR T Cells

    Bioengineers may have found a way to use tamoxifen activated with blue light to control precisely which tissues and body areas CAR T cells attack, reducing toxicities in other parts of the body. They reported their work in ACS Synthetic Biology.

    December 18, 2019
    FDA Approves Enzalutamide for Metastatic Castration-Sensitive Prostate Cancer
    U.S. Food and Drug Administration (FDA)

    FDA Approves Enzalutamide for Metastatic Castration-Sensitive Prostate Cancer

    On December 16, 2019, the U.S. Food and Drug Administration (FDA) approved enzalutamide (Xtandi®) for patients with metastatic castration-sensitive prostate cancer.

    December 17, 2019
    Newer Therapies at Last Offer Systemic Options for Metastatic HCC
    Advanced practice nursing (APN)

    Newer Therapies at Last Offer Systemic Options for Metastatic HCC

    Already the third leading cause of cancer deaths worldwide, hepatocellular carcinoma (HCC) is a continually growing burden as the incidence of obesity, type II diabetes, and hypertension also increase, which may lead to cirrhosis and nonalcoholic fatty liver disease. Its incidence is highest in Asia and Africa, where the prevalence of hepatitis B and hepatitis C may result in chronic liver disease and subsequently HCC. 

    December 12, 2019
    FDA Approves Atezolizumab With Paclitaxel Protein-Bound and Carboplatin for Metastatic NSCLC Without EGFR/ALK Aberrations
    U.S. Food and Drug Administration (FDA)

    FDA Approves Atezolizumab With Paclitaxel Protein-Bound and Carboplatin for Metastatic NSCLC Without EGFR/ALK Aberrations

    On December 3, 2019, the U.S. Food and Drug Administration (FDA) approved atezolizumab (Tecentriq®) in combination with paclitaxel protein-bound and carboplatin for the first-line treatment of adult patients with metastatic non-squamous non-small cell lung cancer (NSCLC) with no EGFR or ALK genomic tumor aberrations.

    December 05, 2019
    CDK4/6 Plus AI Is Effective for Older Women With Breast Cancer
    Breast cancer

    CDK4/6 Plus AI Is Effective for Older Women With Breast Cancer

    Combination treatment with a CDK4/6 inhibitor and aromatase inhibitor (AI) results in similar progression-free survival (PFS) rates in women with hormone receptor-positive, HER2-negative metastatic breast cancer who are aged 70 or older compared to younger women, according to study findings published in the Journal of Clinical Oncology.

    December 04, 2019
    B. Braun Recalls Certain Lots of Blood Administration Sets
    Safety

    B. Braun Recalls Certain Lots of Blood Administration Sets

    Because of the potential for leakage at the joint between the blood filters and tubing, B. Braun issued a voluntary recall of 22 lots of its y-type blood administration sets in November 2019. The recalled sets are used to deliver blood from a container to a patient's vascular system through an IV catheter inserted into a vein or central venous catheter.

    December 03, 2019
    Oncology Drug Reference Sheet: Blinatumomab (Blincyto®)
    Treatments

    Oncology Drug Reference Sheet: Blinatumomab

    Blinatumomab received accelerated approval from the U.S. Food and Drug Administration (FDA) in 2014 for the treatment of B-cell precursor acute lymphoblastic leukemia. The drug’s unique administration procedures have prompted nurses to evaluate their practice for safety.

    November 27, 2019
    FDA Approves Acalabrutinib for CLL and SLL
    U.S. Food and Drug Administration (FDA)

    FDA Approves Acalabrutinib for CLL and SLL

    On November 21, 2019, the U.S. Food and Drug Administration (FDA) approved acalabrutinib (Calquence®) for adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).

    November 21, 2019
    Do Antibiotics Affect Response to Immune Checkpoint Inhibitors?
    Research

    Do Antibiotics Affect Response to Immune Checkpoint Inhibitors?

    Receiving antibiotics in the 30 days prior to starting immune checkpoint inhibitor treatment was associated with significantly reduced median overall survival, according to findings from a study published in JAMA Oncology. However, antibiotic use during treatment had no effect on survival.

    November 20, 2019
    The Case of the Efficacy Explanation
    Treatments

    The Case of the Efficacy Explanation

    Jenni is an oncology nurse practitioner in an outpatient medical oncology clinic. She is meeting with 70-year-old Don after his first cycle of cabozantinib for treatment of metastatic medullary thyroid carcinoma when he asks why the oncologist put him on a pill instead of using IV chemotherapy. “Is it because I don’t have long to live?” Don wonders.

    November 19, 2019
    FDA Grants Accelerated Approval to Zanubrutinib for Mantle Cell Lymphoma
    U.S. Food and Drug Administration (FDA)

    FDA Grants Accelerated Approval to Zanubrutinib for Mantle Cell Lymphoma

    On November 14, 2019, the U.S. Food and Drug Administration (FDA) granted accelerated approval to zanubrutinib (Brukinsa™) for adult patients with mantle cell lymphoma who have received at least one prior therapy.

    November 15, 2019
    FDA Approves Niraparib for HRD-Positive Advanced Ovarian Cancer
    U.S. Food and Drug Administration (FDA)

    FDA Approves Niraparib for HRD-Positive Advanced Ovarian Cancer

    On October 23, 2019, the U.S. Food and Drug Administration (FDA) approved niraparib (Zejula®) for patients with advanced ovarian, fallopian tube, or primary peritoneal cancer treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD)-positive status. HRD is defined by either a deleterious or suspected deleterious BRCA mutation, or genomic instability in patients with disease progression greater than six months after response to the last platinum-based chemotherapy.

    October 24, 2019
    Small Study Shows T-Cell Activity in Pancreatic Cancer
    Research

    Small Study Shows T-Cell Activity in Pancreatic Cancer

    When treated with their own nonengineered T cells plus chemotherapy, six of seven patients with inoperable or metastatic pancreatic cancer showed objective responses or stable disease, according to the results of a study reported at the American Association for Cancer Research’s Immune Cell Therapies for Cancer conference in July 2019.

    October 23, 2019
    Plan Ahead to Ensure Consistency in Patient Care and Communication During Drug Shortages
    U.S. Food and Drug Administration (FDA)

    Plan Ahead to Ensure Consistency in Patient Care and Communication During Drug Shortages

    A manufacturing delay leading to a shipping delay caused the October 2019 vincristine shortage, according to a letter Pfizer sent to its customers on October 18; the U.S. Food and Drug Administration first reported the shortage on October 16. It affects both the 1 mg/ml and 2 mg/2 ml single-dose ONCO-TAIN™ glass fliptop vials.

    October 22, 2019
    Oncology Drug Reference Sheet: Darolutamide (Nubeqa®)
    Treatments

    Oncology Drug Reference Sheet: Darolutamide

    Based on the results of the phase III ARAMIS trial that demonstrated significant improvement in metastasis-free survival, the U.S. Food and Drug Administration approved darolutamide under priority review on July 30, 2019. Darolutamide is approved for nonmetastatic, castration-resistant prostate cancer in men receiving concurrent gonadotropin-releasing hormone therapy or who have had bilateral orchiectomy.

    October 22, 2019
    Getting the Right Treatment at the Right Time Reduces Inequities in Breast Cancer Survival
    Cancer health disparities

    Getting the Right Treatment at the Right Time Reduces Inequities in Breast Cancer Survival

    Although death rates from breast cancer have been falling, the trend has not been equal among all women. Looking at breast cancer survival on a population level can tell us how effective our public health and healthcare systems are at early diagnosis, delivery of evidence-based treatment, and management of follow-up care.

    October 08, 2019
    FDA Approves Daratumumab for Transplant-Eligible Multiple Myeloma
    U.S. Food and Drug Administration (FDA)

    FDA Approves Daratumumab for Transplant-Eligible Multiple Myeloma

    On September 26, 2019, the U.S. Food and Drug Administration (FDA) approved daratumumab (Darzalex®) for adult patients with multiple myeloma in combination with bortezomib, thalidomide, and dexamethasone in newly diagnosed patients who are eligible for autologous stem cell transplant.

    September 26, 2019
    FDA Rolls Out More New Indications for Existing Agents
    U.S. Food and Drug Administration (FDA)

    FDA Rolls Out More New Indications for Existing Agents

    Pembrolizumab, lenalidomide, and avelumab all received new treatment indications in spring 2019. Here’s what you need to know about dosing, adverse events, and other nursing considerations for these and other drugs that the U.S. Food and Drug Administration (FDA) approved from April–June 2019.

    September 25, 2019
    Oncology Drug Reference Sheet: Erdafitinib
    Treatments

    Oncology Drug Reference Sheet: Erdafitinib

    Erdafitinib (Balversa™) is the first targeted therapy that the U.S. Food and Drug Administration approved for treatment of metastatic bladder cancer. 

    September 24, 2019
    FDA Approves Apalutamide for Metastatic Castration-Sensitive Prostate Cancer
    U.S. Food and Drug Administration (FDA)

    FDA Approves Apalutamide for Metastatic Castration-Sensitive Prostate Cancer

    On September 17, 2019, the U.S. Food and Drug Administration (FDA) approved apalutamide (ErleadaTM) for patients with metastatic castration-sensitive prostate cancer. Apalutamide was initially approved in 2018 for patients with non-metastatic castration-resistant prostate cancer.

    September 18, 2019
    Vaccine May Boost CAR T-Cell Activity in Solid Tumors
    Research

    Vaccine May Boost CAR T-Cell Activity in Solid Tumors

    Researchers are testing a new approach using an amphiphilic cancer vaccine to deliver CAR T-cell therapy to solid tumors, and the results of preclinical studies are promising, according to findings published in the journal Science.

    September 18, 2019
    FDA Approves Combination Pembrolizumab Plus Lenvatinib
    U.S. Food and Drug Administration (FDA)

    FDA Approves Combination Pembrolizumab Plus Lenvatinib

    On September 17, 2019, the U.S. Food and Drug Administration (FDA) granted accelerated approval to the combination of pembrolizumab (Keytruda®) plus lenvatinib (Lenvima®) for the treatment of patients with advanced endometrial carcinoma that is not microsatellite instability high (MSI-H) or mismatch repair deficient (dMMR) and who have disease progression following prior systemic therapy but are not candidates for curative surgery or radiation.

    September 17, 2019
    Oncology Formulations Not Affected by Bevacizumab Recall
    Prescription medication

    Oncology Formulations Not Affected by Bevacizumab Recall

    On September 3, 2019, AmEx Pharmacy issued a voluntary recall of two dosages of injectable bevacizumab. Although injectable bevacizumab is used in cancer treatment, the formulations affected by the recall are for much smaller dosages that are used to treat eye diseases (i.e., macular degeneration and diabetic retinopathy).

    September 06, 2019
    Melanoma Death Rates Are Falling Fast, Thanks to Immunotherapy
    Immunotherapy

    Melanoma Death Rates Are Falling Fast, Thanks to Immunotherapy

    Two-year survival rates for patients with advanced melanoma increased quickly after the introduction of ipilimumab in 2011, according to an analysis published the journal Cancer.

    September 04, 2019
    Oncology Drug Reference Sheet: Venetoclax
    Treatments

    Oncology Drug Reference Sheet: Venetoclax

    Venetoclax (Venclexta®) was approved by the U.S. Food and Drug Administration on May 15, 2019, for the treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) as a single agent or in combination therapy. Previously, it had been approved in late 2018 for use in combination therapy for acute myeloid leukemia (AML) in older adults or those with significant comorbidities.

    August 27, 2019
    FDA Approves Fedratinib for Myelofibrosis
    U.S. Food and Drug Administration (FDA)

    FDA Approves Fedratinib for Myelofibrosis

    On August 16, 2019, the U.S. Food and Drug Administration (FDA) approved fedratinib (Inrebic®) for adults with intermediate-2 or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis.

    August 16, 2019
    FDA Approves Entrectinib for NTRK Solid Tumors and ROS-1 NSCLC
    U.S. Food and Drug Administration (FDA)

    FDA Approves Entrectinib for NTRK Solid Tumors and ROS-1 NSCLC

    On August 15, 2019, the U.S. Food and Drug Administration (FDA) granted accelerated approval to entrectinib (RozlytrekTM) for adults and pediatric patients 12 years of age and older with solid tumors that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy.

    August 16, 2019
    CAR T Cells Show Promise in Solid Tumors
    Research

    CAR T Cells Show Promise in Solid Tumors

    Two recent studies demonstrated CAR T-cell therapy activity in certain types of solid tumors, according to results presented at the American Society of Clinical Oncology annual meeting. The CAR T cells used new targets outside of the CD19 targets used for the therapy’s current approvals in leukemia and lymphoma. 
     

    August 14, 2019
    Geriatric Oncology Ambulatory Care Clinics Address Older Patients’ Needs
    Research

    Geriatric Oncology Ambulatory Care Clinics Address Older Patients’ Needs

    Traditionally defined as patients aged 65 and older, older adults make up the majority of patients with cancer. Ambulatory care clinics with a specialized focus on older patients with cancer can provide age-specific care and an interprofessional team of providers well versed in cancer, aging, and geriatric assessment. Through geriatric oncology ambulatory care clinics, providers can work together to identify and coordinate plans to individualize treatment and supportive care for older patients.  

    August 13, 2019
    The Case of the Pregnancy Predicament
    Clinical practice

    The Case of the Pregnancy Predicament

    A 33-year-old woman presents to the emergency department with fever, weight loss, and dyspnea. She is five months pregnant. A computed tomography (CT) chest scan without contrast shows a large mediastinal mass. Biopsy demonstrates Hodgkin lymphoma (HL), but magnetic resonance imaging (MRI) of her abdomen and pelvis without contrast is negative for lymphadenopathy. Her echocardiogram and pulmonary function testing are normal.

    August 02, 2019
    • Current page 1
    • Page 2
    • Page 3
    • Page 4
    • Page 5
    • Page 6
    • Next page
    • Last page Last »
    Trending Topics
    • Treatments
    • Research
    • Safety
    • COVID-19
    • ONS Congress
    • Clinical practice
    • U.S. Food and Drug Administration (FDA)
    • Health Policy
    • Immunotherapy
    • Oncology nurse influence
    View All Topics
    Home
    News, Views, and Advocacy From the Oncology Nursing Society
  • Legal Notices
  • Contact Us
  • Conferences
  • Advertising
  • Newsroom
  • Sitemap
  • Instagram
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • RSS
  • ONS
  • Oncology Nursing Foundation
  • ONCC
  • © Copyright 2021 Oncology Nursing Society
     
    Back to Top ▲